Significance of TFF3 protein and Her-2/neu status in patients with gastric adenocarcinoma

Pathology Research and Practice

Volumn 209, Issue 8, 2013, Pages 479-485

  Xu, Cong cong ^a   Wei, Hong jun ^b   Zhao, Wen wen ^a   Sui, Ai hua ^a   Wang, Xiu mei ^a   Qiu, Wen sheng ^a  

^a QINGDAO UNIVERSITY   (China)

^b QINGDAO MUNICIPAL HOSPITAL   (China)

Author keywords

Gastric cancer; Her 2 neu; Prognosis; TFF3

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; INTESTINAL TREFOIL FACTOR; TREFOIL FACTOR 3; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER PROGNOSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GASTRECTOMY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN EXPRESSION; STOMACH ADENOCARCINOMA;

GASTRIC CANCER; HER-2/NEU; PROGNOSIS; TFF3;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; FEMALE; GASTRECTOMY; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PEPTIDES; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RISK FACTORS; STOMACH NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84881551892     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2013.04.017     Document Type: Article

References (31)

1. Jackson C., Cunningham D., Oliveira J. Gastric cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol. 2009, 20(Suppl. 4):34-36.
2. Bang Y.J., Van Cutsem E., Feyereislova A., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 376:687-697.
3. Halon A., Donizy P., Biecek P., et al. HER-2 expression in immunohistochemistry has no prognostic significance in gastric cancer patients. Sci. World J. 2012, 2012:941259.
4. Hsu J.T., Chen T.C., Tseng J.H., et al. Impact of HER-2 overexpression/amplification on the prognosis of gastric cancer patients undergoing resection: a single-center study of 1,036 patients. Oncologist 2011, 16:1706-1713.
5. Giunciuglio D., Culty M., Fassina G., et al. Invasive phenotype of MCF10A cells overexpressing c-Ha-ras and c-erbB-2 oncogenes. Int. J. Cancer 1995, 63:815-822.
6. Wilson K.S., Roberts H., Leek R., et al. Differential gene expression patterns in HER2/neu-positive and -negative breast cancer cell lines and tissues. Am. J. Pathol. 2002, 161:1171-1185.
7. Kosriwong K., Menheniott T.R., Giraud A.S., et al. Trefoil factors: tumor progression markers and mitogens via EGFR/MAPK activation in cholangiocarcinoma. World J. Gastroenterol. 2011, 17:1631-1641.
8. Liu D., el-Hariry I., Karayiannakis A.J., et al. Phosphorylation of beta-catenin and epidermal growth factor receptor by intestinal trefoil factor. Lab. Invest. 1997, 77:557-563.
9. Rivat C., Rodrigues S., Bruyneel E., et al. Implication of STAT3 signaling in human colonic cancer cells during intestinal trefoil factor 3 (TFF3)- and vascular endothelial growth factor-mediated cellular invasion and tumor growth. Cancer Res. 2005, 65:195-202.
10. Taupin D., Wu D.C., Jeon W.K., et al. The trefoil gene family are coordinately expressed immediate-early genes: EGF receptor- and MAP kinase-dependent interregulation. J. Clin. Invest. 1999, 103:R31-R38.
11. Hoffmann W. Trefoil factors TFF (trefoil factor family) peptide-triggered signals promoting mucosal restitution. Cell. Mol. Life Sci. 2005, 62:2932-2938.
12. Efstathiou J.A., Noda M., Rowan A., et al. Intestinal trefoil factor controls the expression of the adenomatous polyposis coli-catenin and the E-cadherin-catenin complexes in human colon carcinoma cells. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:3122-3127.
13. John R., El-Rouby N.M., Tomasetto C., et al. Expression of TFF3 during multistep colon carcinogenesis. Histol. Histopathol. 2007, 22:743-751.
14. Faith D.A., Isaacs W.B., Morgan J.D., et al. Trefoil factor 3 overexpression in prostatic carcinoma: prognostic importance using tissue microarrays. Prostate 2004, 61:215-227.
15. Dhar D.K., Wang T.C., Tabara H., et al. Expression of trefoil factor family members correlates with patient prognosis and neoangiogenesis. Clin. Cancer Res. 2005, 11:6472-6478.
16. Meng J.R., Tang H.Z., Zhou K.Z., et al. TFF3 and survivin expressions associate with a lower survival rate in gastric cancer. Clin. Exp. Med. 2012.
17. Perez E.A., Suman V.J., Davidson N.E., et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J. Clin. Oncol. 2006, 24:3032-3038.
18. Podolsky D.K., Lynch-Devaney K., Stow J.L., et al. Identification of human intestinal trefoil factor. Goblet cell-specific expression of a peptide targeted for apical secretion. J. Biol. Chem. 1993, 268:12230.
19. Ahmed A.R., Griffiths A.B., Tilby M.T., et al. TFF3 is a normal breast epithelial protein and is associated with differentiated phenotype in early breast cancer but predisposes to invasion and metastasis in advanced disease. Am. J. Pathol. 2012, 180:904-916.
20. Scheble V.J., Scharf G., Braun M., et al. ERG rearrangement in local recurrences compared to distant metastases of castration-resistant prostate cancer. Virchows Arch. 2012, 461:157-162.
21. Takano T., Yamada H. Trefoil factor 3 (TFF3): a promising indicator for diagnosing thyroid follicular carcinoma. Endocr. J. 2009, 56:9-16.
22. Taupin D., Pedersen J., Familari M., et al. Augmented intestinal trefoil factor (TFF3) and loss of pS2 (TFF1) expression precedes metaplastic differentiation of gastric epithelium. Lab. Invest. 2001, 81:397-408.
23. Gallardo A., Lerma E., Escuin D., et al. Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas. Br. J. Cancer 2012, 106:1367-1373.
24. She Q.B., Chandarlapaty S., Ye Q., et al. Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS ONE 2008, 3:e3065.
25. Koumakpayi I.H., Le Page C., Mes-Masson A.M., Saad F. Hierarchical clustering of immunohistochemical analysis of the activated ErbB/PI3K/Akt/NF-kappaB signalling pathway and prognostic significance in prostate cancer. Br. J. Cancer 2010, 102:1163-1173.
26. Tiezzi D.G., Andrade J.M., Ribeiro-Silva A., et al. HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination. BMC Cancer 2007, 7:36.
27. Riou G., Mathieu M.C., Barrois M., et al. c-erbB-2 (HER-2/neu) gene amplification is a better indicator of poor prognosis than protein over-expression in operable breast-cancer patients. Int. J. Cancer 2001, 95:266-270.
28. Ndubisi B., Sanz S., Lu L., et al. The prognostic value of HER-2/neu oncogene in cervical cancer. Ann. Clin. Lab. Sci. 1997, 27:396-401.
29. Sidoni A., Cavaliere A., Bellezza G., et al. Coexpression of HER-2/neu and p53 in breast cancer identifies a subset with an aggressive biopathological profile. Tumori 2006, 92:412-415.
30. Ribeiro M.M., Sarmento J.A., Sobrinho Simoes M.A., Bastos J. Prognostic significance of Lauren and Ming classifications and other pathologic parameters in gastric carcinoma. Cancer 1981, 47:780-784.
31. Naderi A., Hughes-Davies L. A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer. Neoplasia 2008, 10:542-548.